[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fr8Yh5p-Gbya0kVFz2QT1OYvl3wuigfku-kUTg6oZYiM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"University of Patras",[4],68,false,9,21,15731,2,36,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Coronary Artery Disease",6,{"name":18,"count":19},"Platelet Reactivity",5,{"name":21,"count":19},"Morbid Obesity",{"name":23,"count":24},"Acute Coronary Syndrome",4,{"name":26,"count":27},"Sport Injury",3,{"name":29,"count":11},"Coronary Artery Disease (CAD)",{"name":31,"count":11},"Diastasis Recti Abdominis (DRA)",{"name":33,"count":11},"Diastasis Recti And Weakness Of The Linea Alba",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07491523","Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD","2026-07","Antifibrotic drugs",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,74,92,201,284,322,340,366,384,409,427,453,471,489,519,537,555,573,600,618,636,666,684,702,720,738,756,787,805,823,841,859,877,902,920,948,966,984,1002,1020,1038,1060,1084,1102,1129,1147,1171,1196,1222],{"intervention":39,"totalTrials":49,"cells":50},1,{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":58,"PHASE4":60,"NA":62},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":53},[],{"trials":59,"activeCount":53},[],{"trials":61,"activeCount":53},[],{"trials":63,"activeCount":49,"soonestReadout":38},[64],{"nctId":36,"briefTitle":37,"status":65,"phases":66,"primaryCompletion":38,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":72},"RECRUITING",[],"2027-03","2025-06-01",35,[71],"SSc-Systemic Sclerosis",[39,73],"MMF Immunosuppression",{"intervention":73,"totalTrials":49,"cells":75},{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":86},{"trials":77,"activeCount":53},[],{"trials":79,"activeCount":53},[],{"trials":81,"activeCount":53},[],{"trials":83,"activeCount":53},[],{"trials":85,"activeCount":53},[],{"trials":87,"activeCount":49,"soonestReadout":38},[88],{"nctId":36,"briefTitle":37,"status":65,"phases":89,"primaryCompletion":38,"completion":67,"start":68,"enrollment":69,"conditions":90,"interventions":91},[],[71],[39,73],{"intervention":93,"totalTrials":94,"cells":95},"Prasugrel",10,{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":154,"NA":199},{"trials":97,"activeCount":53},[],{"trials":99,"activeCount":53},[],{"trials":101,"activeCount":53},[],{"trials":103,"activeCount":53},[104,115,123,134,144],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":113},"NCT01304472","Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment","COMPLETED",[44],"2011-04","2011-02",25,[29],[93,114],"Clopidogrel",{"nctId":116,"briefTitle":117,"status":107,"phases":118,"primaryCompletion":119,"completion":119,"start":109,"enrollment":69,"conditions":120,"interventions":122},"NCT01338909","Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)",[44],"2011-09",[121],"Myocardial Infarction",[93,114],{"nctId":124,"briefTitle":125,"status":107,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":133},"NCT01155765","Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis",[44],"2010-07","2010-05",70,[131,132],"Hemodialysis","Chronic Renal Failure",[93,114],{"nctId":135,"briefTitle":136,"status":107,"phases":137,"primaryCompletion":127,"completion":127,"start":138,"enrollment":129,"conditions":139,"interventions":141},"NCT01109784","Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).",[44],"2010-04",[29,140],"Acute Coronary Syndrome (ACS)",[142,143],"prasugrel","clopidogrel",{"nctId":145,"briefTitle":146,"status":107,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":152},"NCT01360437","Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention",[44],"2011-12","2011-05",44,[15,23],[93,153],"Ticagrelor",{"trials":155,"activeCount":53},[156,164,173,181,189],{"nctId":157,"briefTitle":158,"status":107,"phases":159,"primaryCompletion":160,"completion":160,"start":160,"enrollment":161,"conditions":162,"interventions":163},"NCT01642966","Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention",[45],"2012-09",56,[23],[93,153],{"nctId":165,"briefTitle":166,"status":107,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT01463150","Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and\u002For Weighing \u003C60 kg Post Percutaneous Coronary Intervention (PCI)",[45],"2012-07","2011-10",27,[18],[114,93],{"nctId":174,"briefTitle":175,"status":107,"phases":176,"primaryCompletion":177,"completion":177,"start":169,"enrollment":178,"conditions":179,"interventions":180},"NCT01463163","Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)",[45],"2012-04",50,[18],[93,153],{"nctId":182,"briefTitle":183,"status":107,"phases":184,"primaryCompletion":160,"completion":160,"start":185,"enrollment":186,"conditions":187,"interventions":188},"NCT01642940","Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study",[45],"2012-06",30,[15,23],[93,153],{"nctId":190,"briefTitle":191,"status":107,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT01957540","Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease",[45],"2015-12","2014-06",22,[15,197],"Endothelial Function",[153,93],{"trials":200,"activeCount":53},[],{"intervention":153,"totalTrials":94,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":234,"NA":282},{"trials":204,"activeCount":53},[],{"trials":206,"activeCount":53},[],{"trials":208,"activeCount":53},[],{"trials":210,"activeCount":53},[211,221,230],{"nctId":212,"briefTitle":213,"status":107,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":219},"NCT01961856","Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.",[44],"2014-02","2013-09",74,[18],[220,153],"Clopidogrel and Ticagrelor",{"nctId":222,"briefTitle":223,"status":107,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},"NCT01511471","Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis",[44],"2012-02","2012-01",20,[18],[153],{"nctId":145,"briefTitle":146,"status":107,"phases":231,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":232,"interventions":233},[44],[15,23],[93,153],{"trials":235,"activeCount":53},[236,240,251,255,264,268,272],{"nctId":157,"briefTitle":158,"status":107,"phases":237,"primaryCompletion":160,"completion":160,"start":160,"enrollment":161,"conditions":238,"interventions":239},[45],[23],[93,153],{"nctId":241,"briefTitle":242,"status":107,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":249},"NCT02108808","Effect of Ticagrelor on Fractional Flow Reserve",[45],"2014-10","2014-04",76,[248],"Fractional Flow Reserve",[153,250],"Prasugrel or Clopidogrel",{"nctId":174,"briefTitle":175,"status":107,"phases":252,"primaryCompletion":177,"completion":177,"start":169,"enrollment":178,"conditions":253,"interventions":254},[45],[18],[93,153],{"nctId":256,"briefTitle":257,"status":107,"phases":258,"primaryCompletion":259,"completion":259,"start":177,"enrollment":260,"conditions":261,"interventions":263},"NCT01575795","Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)",[45],"2013-02",83,[262],"ST-elevation Myocardial Infarction",[153,153],{"nctId":182,"briefTitle":183,"status":107,"phases":265,"primaryCompletion":160,"completion":160,"start":185,"enrollment":186,"conditions":266,"interventions":267},[45],[15,23],[93,153],{"nctId":190,"briefTitle":191,"status":107,"phases":269,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":270,"interventions":271},[45],[15,197],[153,93],{"nctId":273,"briefTitle":274,"status":107,"phases":275,"primaryCompletion":276,"completion":276,"start":277,"enrollment":227,"conditions":278,"interventions":281},"NCT02663713","A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction",[45],"2017-06","2017-01",[121,279,280,15],"Diabetes Mellitus","Renal Disease",[153,114],{"trials":283,"activeCount":53},[],{"intervention":114,"totalTrials":16,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":310,"NA":320},{"trials":287,"activeCount":53},[],{"trials":289,"activeCount":53},[],{"trials":291,"activeCount":53},[],{"trials":293,"activeCount":53},[294,298,302,306],{"nctId":105,"briefTitle":106,"status":107,"phases":295,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":296,"interventions":297},[44],[29],[93,114],{"nctId":116,"briefTitle":117,"status":107,"phases":299,"primaryCompletion":119,"completion":119,"start":109,"enrollment":69,"conditions":300,"interventions":301},[44],[121],[93,114],{"nctId":124,"briefTitle":125,"status":107,"phases":303,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":304,"interventions":305},[44],[131,132],[93,114],{"nctId":135,"briefTitle":136,"status":107,"phases":307,"primaryCompletion":127,"completion":127,"start":138,"enrollment":129,"conditions":308,"interventions":309},[44],[29,140],[142,143],{"trials":311,"activeCount":53},[312,316],{"nctId":165,"briefTitle":166,"status":107,"phases":313,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":314,"interventions":315},[45],[18],[114,93],{"nctId":273,"briefTitle":274,"status":107,"phases":317,"primaryCompletion":276,"completion":276,"start":277,"enrollment":227,"conditions":318,"interventions":319},[45],[121,279,280,15],[153,114],{"trials":321,"activeCount":53},[],{"intervention":250,"totalTrials":49,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":338},{"trials":325,"activeCount":53},[],{"trials":327,"activeCount":53},[],{"trials":329,"activeCount":53},[],{"trials":331,"activeCount":53},[],{"trials":333,"activeCount":53},[334],{"nctId":241,"briefTitle":242,"status":107,"phases":335,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":336,"interventions":337},[45],[248],[153,250],{"trials":339,"activeCount":53},[],{"intervention":341,"totalTrials":49,"cells":342},"High dose of Unfractionated Heparin",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":364},{"trials":344,"activeCount":53},[],{"trials":346,"activeCount":53},[],{"trials":348,"activeCount":53},[],{"trials":350,"activeCount":53},[],{"trials":352,"activeCount":53},[353],{"nctId":354,"briefTitle":355,"status":107,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT02570243","High (100IU\u002FKg) Versus Standard (50IU\u002FKg) Heparin Dose for Prevention of Forearm Artery Occlusion",[45],"2017-09","2015-02",1800,[361],"Coronary Angiography",[341,363],"Standard dose of Unfractionated heparin",{"trials":365,"activeCount":53},[],{"intervention":363,"totalTrials":49,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":382},{"trials":369,"activeCount":53},[],{"trials":371,"activeCount":53},[],{"trials":373,"activeCount":53},[],{"trials":375,"activeCount":53},[],{"trials":377,"activeCount":53},[378],{"nctId":354,"briefTitle":355,"status":107,"phases":379,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":380,"interventions":381},[45],[361],[341,363],{"trials":383,"activeCount":53},[],{"intervention":385,"totalTrials":49,"cells":386},"Ticagrelor 180mg whole",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":407},{"trials":388,"activeCount":53},[],{"trials":390,"activeCount":53},[],{"trials":392,"activeCount":53},[],{"trials":394,"activeCount":53},[],{"trials":396,"activeCount":53},[397],{"nctId":398,"briefTitle":399,"status":107,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":227,"conditions":403,"interventions":405},"NCT02046486","OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic\u002FPharmacodynamic Study (the LIQUID Study)",[45],"2015-01","2014-01",[404],"ST Elevation Myocardial Infarction",[385,406],"Ticagrelor 180mg crushed and dispersed",{"trials":408,"activeCount":53},[],{"intervention":406,"totalTrials":49,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":425},{"trials":412,"activeCount":53},[],{"trials":414,"activeCount":53},[],{"trials":416,"activeCount":53},[],{"trials":418,"activeCount":53},[],{"trials":420,"activeCount":53},[421],{"nctId":398,"briefTitle":399,"status":107,"phases":422,"primaryCompletion":401,"completion":401,"start":402,"enrollment":227,"conditions":423,"interventions":424},[45],[404],[385,406],{"trials":426,"activeCount":53},[],{"intervention":428,"totalTrials":49,"cells":429},"Ticagrelor 180mg loading dose and 90mg bid maintenance dose",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":451},{"trials":431,"activeCount":53},[],{"trials":433,"activeCount":53},[],{"trials":435,"activeCount":53},[],{"trials":437,"activeCount":53},[],{"trials":439,"activeCount":53},[440],{"nctId":441,"briefTitle":442,"status":107,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":161,"conditions":446,"interventions":449},"NCT01950416","Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis",[45],"2014-12","2013-03",[404,447,448],"Fibrinolysis","P2Y12 Inhibitor",[428,450],"Clopidogrel 600mg loading dose and 150mg maintenance dose",{"trials":452,"activeCount":53},[],{"intervention":450,"totalTrials":49,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":469},{"trials":456,"activeCount":53},[],{"trials":458,"activeCount":53},[],{"trials":460,"activeCount":53},[],{"trials":462,"activeCount":53},[],{"trials":464,"activeCount":53},[465],{"nctId":441,"briefTitle":442,"status":107,"phases":466,"primaryCompletion":444,"completion":444,"start":445,"enrollment":161,"conditions":467,"interventions":468},[45],[404,447,448],[428,450],{"trials":470,"activeCount":53},[],{"intervention":220,"totalTrials":49,"cells":472},{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":485,"NA":487},{"trials":474,"activeCount":53},[],{"trials":476,"activeCount":53},[],{"trials":478,"activeCount":53},[],{"trials":480,"activeCount":53},[481],{"nctId":212,"briefTitle":213,"status":107,"phases":482,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":483,"interventions":484},[44],[18],[220,153],{"trials":486,"activeCount":53},[],{"trials":488,"activeCount":53},[],{"intervention":490,"totalTrials":49,"cells":491},"Dexmedetomidine",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":515,"NA":517},{"trials":493,"activeCount":53},[],{"trials":495,"activeCount":53},[],{"trials":497,"activeCount":53},[],{"trials":499,"activeCount":53},[500],{"nctId":501,"briefTitle":502,"status":107,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":178,"conditions":507,"interventions":511},"NCT06185127","Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy",[44],"2020-05-31","2020-08-31","2019-09-01",[508,509,510],"Lung Diseases","Diagnosis","Anesthesia",[490,512,513,514],"Ketamine","Midazolam","Fentanyl",{"trials":516,"activeCount":53},[],{"trials":518,"activeCount":53},[],{"intervention":512,"totalTrials":49,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":533,"NA":535},{"trials":522,"activeCount":53},[],{"trials":524,"activeCount":53},[],{"trials":526,"activeCount":53},[],{"trials":528,"activeCount":53},[529],{"nctId":501,"briefTitle":502,"status":107,"phases":530,"primaryCompletion":504,"completion":505,"start":506,"enrollment":178,"conditions":531,"interventions":532},[44],[508,509,510],[490,512,513,514],{"trials":534,"activeCount":53},[],{"trials":536,"activeCount":53},[],{"intervention":513,"totalTrials":49,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":545,"PHASE4":551,"NA":553},{"trials":540,"activeCount":53},[],{"trials":542,"activeCount":53},[],{"trials":544,"activeCount":53},[],{"trials":546,"activeCount":53},[547],{"nctId":501,"briefTitle":502,"status":107,"phases":548,"primaryCompletion":504,"completion":505,"start":506,"enrollment":178,"conditions":549,"interventions":550},[44],[508,509,510],[490,512,513,514],{"trials":552,"activeCount":53},[],{"trials":554,"activeCount":53},[],{"intervention":514,"totalTrials":49,"cells":556},{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":569,"NA":571},{"trials":558,"activeCount":53},[],{"trials":560,"activeCount":53},[],{"trials":562,"activeCount":53},[],{"trials":564,"activeCount":53},[565],{"nctId":501,"briefTitle":502,"status":107,"phases":566,"primaryCompletion":504,"completion":505,"start":506,"enrollment":178,"conditions":567,"interventions":568},[44],[508,509,510],[490,512,513,514],{"trials":570,"activeCount":53},[],{"trials":572,"activeCount":53},[],{"intervention":574,"totalTrials":49,"cells":575},"Sevoflurane",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":596,"NA":598},{"trials":577,"activeCount":53},[],{"trials":579,"activeCount":53},[],{"trials":581,"activeCount":53},[],{"trials":583,"activeCount":53},[584],{"nctId":585,"briefTitle":586,"status":587,"phases":588,"primaryCompletion":589,"completion":590,"start":138,"enrollment":591,"conditions":592,"interventions":593},"NCT01279499","Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients","UNKNOWN",[43,44],"2011-06","2011-07",100,[21],[574,574,594,595],"Propofol- Remifentanyl","Propofol, Remifentanyl",{"trials":597,"activeCount":53},[],{"trials":599,"activeCount":53},[],{"intervention":594,"totalTrials":49,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":614,"NA":616},{"trials":603,"activeCount":53},[],{"trials":605,"activeCount":53},[],{"trials":607,"activeCount":53},[],{"trials":609,"activeCount":53},[610],{"nctId":585,"briefTitle":586,"status":587,"phases":611,"primaryCompletion":589,"completion":590,"start":138,"enrollment":591,"conditions":612,"interventions":613},[43,44],[21],[574,574,594,595],{"trials":615,"activeCount":53},[],{"trials":617,"activeCount":53},[],{"intervention":595,"totalTrials":49,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":632,"NA":634},{"trials":621,"activeCount":53},[],{"trials":623,"activeCount":53},[],{"trials":625,"activeCount":53},[],{"trials":627,"activeCount":53},[628],{"nctId":585,"briefTitle":586,"status":587,"phases":629,"primaryCompletion":589,"completion":590,"start":138,"enrollment":591,"conditions":630,"interventions":631},[43,44],[21],[574,574,594,595],{"trials":633,"activeCount":53},[],{"trials":635,"activeCount":53},[],{"intervention":637,"totalTrials":49,"cells":638},"Bupivacaine- Fentanyl - Normal Saline",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":662,"NA":664},{"trials":640,"activeCount":53},[],{"trials":642,"activeCount":53},[],{"trials":644,"activeCount":53},[],{"trials":646,"activeCount":53},[647],{"nctId":648,"briefTitle":649,"status":587,"phases":650,"primaryCompletion":160,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":656},"NCT01558713","Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections",[43,44],"2012-12","2010-01",120,[655],"Stillborn Caesarean Section",[637,657,658,659,660,661],"Ropivacaine-Fentanyl-Normal Saline","Levobupivacaine- Fentanyl- Normal Saline","Bupivacaine + Fentanyl","Ropivacaine + Fentanyl","Levobupivacaine + Fentanyl",{"trials":663,"activeCount":53},[],{"trials":665,"activeCount":53},[],{"intervention":657,"totalTrials":49,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":680,"NA":682},{"trials":669,"activeCount":53},[],{"trials":671,"activeCount":53},[],{"trials":673,"activeCount":53},[],{"trials":675,"activeCount":53},[676],{"nctId":648,"briefTitle":649,"status":587,"phases":677,"primaryCompletion":160,"completion":651,"start":652,"enrollment":653,"conditions":678,"interventions":679},[43,44],[655],[637,657,658,659,660,661],{"trials":681,"activeCount":53},[],{"trials":683,"activeCount":53},[],{"intervention":658,"totalTrials":49,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":698,"NA":700},{"trials":687,"activeCount":53},[],{"trials":689,"activeCount":53},[],{"trials":691,"activeCount":53},[],{"trials":693,"activeCount":53},[694],{"nctId":648,"briefTitle":649,"status":587,"phases":695,"primaryCompletion":160,"completion":651,"start":652,"enrollment":653,"conditions":696,"interventions":697},[43,44],[655],[637,657,658,659,660,661],{"trials":699,"activeCount":53},[],{"trials":701,"activeCount":53},[],{"intervention":659,"totalTrials":49,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":716,"NA":718},{"trials":705,"activeCount":53},[],{"trials":707,"activeCount":53},[],{"trials":709,"activeCount":53},[],{"trials":711,"activeCount":53},[712],{"nctId":648,"briefTitle":649,"status":587,"phases":713,"primaryCompletion":160,"completion":651,"start":652,"enrollment":653,"conditions":714,"interventions":715},[43,44],[655],[637,657,658,659,660,661],{"trials":717,"activeCount":53},[],{"trials":719,"activeCount":53},[],{"intervention":660,"totalTrials":49,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":734,"NA":736},{"trials":723,"activeCount":53},[],{"trials":725,"activeCount":53},[],{"trials":727,"activeCount":53},[],{"trials":729,"activeCount":53},[730],{"nctId":648,"briefTitle":649,"status":587,"phases":731,"primaryCompletion":160,"completion":651,"start":652,"enrollment":653,"conditions":732,"interventions":733},[43,44],[655],[637,657,658,659,660,661],{"trials":735,"activeCount":53},[],{"trials":737,"activeCount":53},[],{"intervention":661,"totalTrials":49,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":752,"NA":754},{"trials":741,"activeCount":53},[],{"trials":743,"activeCount":53},[],{"trials":745,"activeCount":53},[],{"trials":747,"activeCount":53},[748],{"nctId":648,"briefTitle":649,"status":587,"phases":749,"primaryCompletion":160,"completion":651,"start":652,"enrollment":653,"conditions":750,"interventions":751},[43,44],[655],[637,657,658,659,660,661],{"trials":753,"activeCount":53},[],{"trials":755,"activeCount":53},[],{"intervention":757,"totalTrials":49,"cells":758},"GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":783,"NA":785},{"trials":760,"activeCount":53},[],{"trials":762,"activeCount":53},[],{"trials":764,"activeCount":53},[],{"trials":766,"activeCount":53},[767],{"nctId":768,"briefTitle":769,"status":107,"phases":770,"primaryCompletion":771,"completion":160,"start":652,"enrollment":772,"conditions":773,"interventions":777},"NCT01249872","Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens",[43,44],"2012-08",96,[21,774,775,776],"Postoperative Pain","Postoperative Bowel Function","Postoperative Ambulation",[757,778,779,780,781,782],"GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE","GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE","GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE","GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE","GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE",{"trials":784,"activeCount":53},[],{"trials":786,"activeCount":53},[],{"intervention":778,"totalTrials":49,"cells":788},{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":801,"NA":803},{"trials":790,"activeCount":53},[],{"trials":792,"activeCount":53},[],{"trials":794,"activeCount":53},[],{"trials":796,"activeCount":53},[797],{"nctId":768,"briefTitle":769,"status":107,"phases":798,"primaryCompletion":771,"completion":160,"start":652,"enrollment":772,"conditions":799,"interventions":800},[43,44],[21,774,775,776],[757,778,779,780,781,782],{"trials":802,"activeCount":53},[],{"trials":804,"activeCount":53},[],{"intervention":779,"totalTrials":49,"cells":806},{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":819,"NA":821},{"trials":808,"activeCount":53},[],{"trials":810,"activeCount":53},[],{"trials":812,"activeCount":53},[],{"trials":814,"activeCount":53},[815],{"nctId":768,"briefTitle":769,"status":107,"phases":816,"primaryCompletion":771,"completion":160,"start":652,"enrollment":772,"conditions":817,"interventions":818},[43,44],[21,774,775,776],[757,778,779,780,781,782],{"trials":820,"activeCount":53},[],{"trials":822,"activeCount":53},[],{"intervention":780,"totalTrials":49,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":837,"NA":839},{"trials":826,"activeCount":53},[],{"trials":828,"activeCount":53},[],{"trials":830,"activeCount":53},[],{"trials":832,"activeCount":53},[833],{"nctId":768,"briefTitle":769,"status":107,"phases":834,"primaryCompletion":771,"completion":160,"start":652,"enrollment":772,"conditions":835,"interventions":836},[43,44],[21,774,775,776],[757,778,779,780,781,782],{"trials":838,"activeCount":53},[],{"trials":840,"activeCount":53},[],{"intervention":781,"totalTrials":49,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":855,"NA":857},{"trials":844,"activeCount":53},[],{"trials":846,"activeCount":53},[],{"trials":848,"activeCount":53},[],{"trials":850,"activeCount":53},[851],{"nctId":768,"briefTitle":769,"status":107,"phases":852,"primaryCompletion":771,"completion":160,"start":652,"enrollment":772,"conditions":853,"interventions":854},[43,44],[21,774,775,776],[757,778,779,780,781,782],{"trials":856,"activeCount":53},[],{"trials":858,"activeCount":53},[],{"intervention":782,"totalTrials":49,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":873,"NA":875},{"trials":862,"activeCount":53},[],{"trials":864,"activeCount":53},[],{"trials":866,"activeCount":53},[],{"trials":868,"activeCount":53},[869],{"nctId":768,"briefTitle":769,"status":107,"phases":870,"primaryCompletion":771,"completion":160,"start":652,"enrollment":772,"conditions":871,"interventions":872},[43,44],[21,774,775,776],[757,778,779,780,781,782],{"trials":874,"activeCount":53},[],{"trials":876,"activeCount":53},[],{"intervention":878,"totalTrials":49,"cells":879},"Sugammadex",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":898,"NA":900},{"trials":881,"activeCount":53},[],{"trials":883,"activeCount":53},[],{"trials":885,"activeCount":53},[],{"trials":887,"activeCount":53},[888],{"nctId":889,"briefTitle":890,"status":587,"phases":891,"primaryCompletion":892,"completion":893,"start":226,"enrollment":653,"conditions":894,"interventions":896},"NCT01629394","Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients",[43,44],"2012-10","2012-11",[21,895],"Neuromuscular Blockade",[878,878,897,897,878,878,897,897],"Neostigmine",{"trials":899,"activeCount":53},[],{"trials":901,"activeCount":53},[],{"intervention":897,"totalTrials":49,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":916,"NA":918},{"trials":905,"activeCount":53},[],{"trials":907,"activeCount":53},[],{"trials":909,"activeCount":53},[],{"trials":911,"activeCount":53},[912],{"nctId":889,"briefTitle":890,"status":587,"phases":913,"primaryCompletion":892,"completion":893,"start":226,"enrollment":653,"conditions":914,"interventions":915},[43,44],[21,895],[878,878,897,897,878,878,897,897],{"trials":917,"activeCount":53},[],{"trials":919,"activeCount":53},[],{"intervention":921,"totalTrials":49,"cells":922},"Bupivacaine plain",{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":944,"NA":946},{"trials":924,"activeCount":53},[],{"trials":926,"activeCount":53},[],{"trials":928,"activeCount":53},[],{"trials":930,"activeCount":53},[931],{"nctId":932,"briefTitle":933,"status":587,"phases":934,"primaryCompletion":177,"completion":935,"start":652,"enrollment":936,"conditions":937,"interventions":938},"NCT01582607","Subarachnoid Administration of Levobupivacaine for Cesarean Section",[43,44],"2012-05",130,[655],[921,939,940,941,942,943],"Ropivacaine plain","Levobupivacaine plain","bupivacaine plain +fentanyl","ropivacaine plain +. fentanyl","Levobupivacaine plain +fentanyl",{"trials":945,"activeCount":53},[],{"trials":947,"activeCount":53},[],{"intervention":939,"totalTrials":49,"cells":949},{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":962,"NA":964},{"trials":951,"activeCount":53},[],{"trials":953,"activeCount":53},[],{"trials":955,"activeCount":53},[],{"trials":957,"activeCount":53},[958],{"nctId":932,"briefTitle":933,"status":587,"phases":959,"primaryCompletion":177,"completion":935,"start":652,"enrollment":936,"conditions":960,"interventions":961},[43,44],[655],[921,939,940,941,942,943],{"trials":963,"activeCount":53},[],{"trials":965,"activeCount":53},[],{"intervention":940,"totalTrials":49,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":980,"NA":982},{"trials":969,"activeCount":53},[],{"trials":971,"activeCount":53},[],{"trials":973,"activeCount":53},[],{"trials":975,"activeCount":53},[976],{"nctId":932,"briefTitle":933,"status":587,"phases":977,"primaryCompletion":177,"completion":935,"start":652,"enrollment":936,"conditions":978,"interventions":979},[43,44],[655],[921,939,940,941,942,943],{"trials":981,"activeCount":53},[],{"trials":983,"activeCount":53},[],{"intervention":941,"totalTrials":49,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":992,"PHASE4":998,"NA":1000},{"trials":987,"activeCount":53},[],{"trials":989,"activeCount":53},[],{"trials":991,"activeCount":53},[],{"trials":993,"activeCount":53},[994],{"nctId":932,"briefTitle":933,"status":587,"phases":995,"primaryCompletion":177,"completion":935,"start":652,"enrollment":936,"conditions":996,"interventions":997},[43,44],[655],[921,939,940,941,942,943],{"trials":999,"activeCount":53},[],{"trials":1001,"activeCount":53},[],{"intervention":942,"totalTrials":49,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1016,"NA":1018},{"trials":1005,"activeCount":53},[],{"trials":1007,"activeCount":53},[],{"trials":1009,"activeCount":53},[],{"trials":1011,"activeCount":53},[1012],{"nctId":932,"briefTitle":933,"status":587,"phases":1013,"primaryCompletion":177,"completion":935,"start":652,"enrollment":936,"conditions":1014,"interventions":1015},[43,44],[655],[921,939,940,941,942,943],{"trials":1017,"activeCount":53},[],{"trials":1019,"activeCount":53},[],{"intervention":943,"totalTrials":49,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1034,"NA":1036},{"trials":1023,"activeCount":53},[],{"trials":1025,"activeCount":53},[],{"trials":1027,"activeCount":53},[],{"trials":1029,"activeCount":53},[1030],{"nctId":932,"briefTitle":933,"status":587,"phases":1031,"primaryCompletion":177,"completion":935,"start":652,"enrollment":936,"conditions":1032,"interventions":1033},[43,44],[655],[921,939,940,941,942,943],{"trials":1035,"activeCount":53},[],{"trials":1037,"activeCount":53},[],{"intervention":1039,"totalTrials":49,"cells":1040},"Adenosine infusion at 200μg\u002FKg\u002Fmin",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1056,"NA":1058},{"trials":1042,"activeCount":53},[],{"trials":1044,"activeCount":53},[],{"trials":1046,"activeCount":53},[],{"trials":1048,"activeCount":53},[1049],{"nctId":1050,"briefTitle":1051,"status":107,"phases":1052,"primaryCompletion":1053,"completion":1053,"start":401,"enrollment":186,"conditions":1054,"interventions":1055},"NCT02350439","Differential Effect of High (200μg\u002Fkg\u002FMin) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg\u002Fkg\u002FMin).",[44],"2015-10",[15],[1039],{"trials":1057,"activeCount":53},[],{"trials":1059,"activeCount":53},[],{"intervention":1061,"totalTrials":49,"cells":1062},"Prasugrel 100mg loading dose",{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1080,"NA":1082},{"trials":1064,"activeCount":53},[],{"trials":1066,"activeCount":53},[],{"trials":1068,"activeCount":53},[],{"trials":1070,"activeCount":53},[1071],{"nctId":1072,"briefTitle":1073,"status":107,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":185,"enrollment":1076,"conditions":1077,"interventions":1078},"NCT01835353","High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)",[44],"2013-07",82,[18],[1061,1079],"Prasugrel 60mg loading dose",{"trials":1081,"activeCount":53},[],{"trials":1083,"activeCount":53},[],{"intervention":1079,"totalTrials":49,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1098,"NA":1100},{"trials":1087,"activeCount":53},[],{"trials":1089,"activeCount":53},[],{"trials":1091,"activeCount":53},[],{"trials":1093,"activeCount":53},[1094],{"nctId":1072,"briefTitle":1073,"status":107,"phases":1095,"primaryCompletion":1075,"completion":1075,"start":185,"enrollment":1076,"conditions":1096,"interventions":1097},[44],[18],[1061,1079],{"trials":1099,"activeCount":53},[],{"trials":1101,"activeCount":53},[],{"intervention":1103,"totalTrials":49,"cells":1104},"ACTH",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1106,"activeCount":53},[],{"trials":1108,"activeCount":53},[],{"trials":1110,"activeCount":53},[],{"trials":1112,"activeCount":53},[],{"trials":1114,"activeCount":53},[],{"trials":1116,"activeCount":53},[1117],{"nctId":1118,"briefTitle":1119,"status":587,"phases":1120,"primaryCompletion":1121,"completion":1122,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1127},"NCT04306653","ACTH vs Betamethasone in Hospitalized Patients With Acute Gout",[46],"2020-04","2020-05","2018-01-05",60,[1126],"Gout Attack",[1103,1128],"Betamethasone",{"intervention":1128,"totalTrials":49,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1132,"activeCount":53},[],{"trials":1134,"activeCount":53},[],{"trials":1136,"activeCount":53},[],{"trials":1138,"activeCount":53},[],{"trials":1140,"activeCount":53},[],{"trials":1142,"activeCount":53},[1143],{"nctId":1118,"briefTitle":1119,"status":587,"phases":1144,"primaryCompletion":1121,"completion":1122,"start":1123,"enrollment":1124,"conditions":1145,"interventions":1146},[46],[1126],[1103,1128],{"intervention":1148,"totalTrials":49,"cells":1149},"Salbutamol",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1151,"activeCount":53},[],{"trials":1153,"activeCount":53},[],{"trials":1155,"activeCount":53},[],{"trials":1157,"activeCount":53},[],{"trials":1159,"activeCount":53},[],{"trials":1161,"activeCount":53},[1162],{"nctId":1163,"briefTitle":1164,"status":107,"phases":1165,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":591,"conditions":1168,"interventions":1170},"NCT01067534","Bronchodilator Responsiveness in Healthy Young Adults Using Forced Oscillations Technique (FOT)",[46],"2011-01","2010-02",[1169],"Bronchodilation",[1148],{"intervention":1172,"totalTrials":49,"cells":1173},"Leuprolide Acetate",{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1175,"activeCount":53},[],{"trials":1177,"activeCount":53},[],{"trials":1179,"activeCount":53},[],{"trials":1181,"activeCount":53},[],{"trials":1183,"activeCount":53},[],{"trials":1185,"activeCount":53},[1186],{"nctId":1187,"briefTitle":1188,"status":107,"phases":1189,"primaryCompletion":1190,"completion":1190,"start":1191,"enrollment":1124,"conditions":1192,"interventions":1195},"NCT06106932","GnRH-a on Angiogenesis of Endometriosis",[46],"2023-01","2015-09",[1193,1194],"Angiogenesis","Endometriosis",[1172],{"intervention":1197,"totalTrials":49,"cells":1198},"SGLT2 inhibitor",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1200,"activeCount":53},[],{"trials":1202,"activeCount":53},[],{"trials":1204,"activeCount":53},[],{"trials":1206,"activeCount":53},[],{"trials":1208,"activeCount":53},[],{"trials":1210,"activeCount":53},[1211],{"nctId":1212,"briefTitle":1213,"status":587,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1221},"NCT05408936","SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers",[],"2023-12-01","2024-06-01","2022-06-03",80,[1220],"Diabetes Mellitus, Type 2",[1197],{"intervention":1223,"totalTrials":49,"cells":1224},"Approved vaccines against Sars-Cov2",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1226,"activeCount":53},[],{"trials":1228,"activeCount":53},[],{"trials":1230,"activeCount":53},[],{"trials":1232,"activeCount":53},[],{"trials":1234,"activeCount":53},[],{"trials":1236,"activeCount":53},[1237],{"nctId":1238,"briefTitle":1239,"status":107,"phases":1240,"primaryCompletion":1241,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1247},"NCT04954651","Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines",[],"2022-03-28","2021-07-07",1000,[1245,1246],"SARS-CoV2 Infection","Vaccine Reaction",[1223]]